Antihypertensive and lipid-lowering treatment to prevent heart attack trial: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | {{SI}} | ||
{{CMG}} | {{CMG}} | ||
| Line 25: | Line 26: | ||
==Results== | ==Results== | ||
The [[alpha blocker]] arm ([[doxazosin]]) was dropped early due to futility. | The [[alpha blocker]] arm ([[doxazosin]]) was dropped early due to futility. | ||
*There were no significant differences among the comparator arms in the primary outcome. | |||
*With respect to stroke ACEi was better than the diuretic or CCB | |||
*With respect to heart Failure ACEi/CCB was better than the diuretic | |||
==References== | ==References== | ||
Revision as of 04:14, 4 October 2012
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) trial compared major outcomes in high risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
Design
Randomized, double-blind, multi-center clinical trial
Interventions
Control arm:
Comparators:
Endpoint
Determine whether occurrence of fatal CHD or nonfatal MI is lower for high-risk hypertensive patients treated with newer agents (CCB, ACEI, alpha-blocker) compared with a diuretic
Population
42,418 high-risk hypertensive patients ≥ 55 years
Results
The alpha blocker arm (doxazosin) was dropped early due to futility.
- There were no significant differences among the comparator arms in the primary outcome.
- With respect to stroke ACEi was better than the diuretic or CCB
- With respect to heart Failure ACEi/CCB was better than the diuretic